The drug, marketed in Europe as Acomplia

Now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the U.K., Germany and a dozen other countries, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans.

The drug, marketed in Europe as Acomplia, will be sold in the United States as Zimulti if approved by the FDA. Whatever the trade name, rimonabant has been hailed by some doctors on the basis of clinical trials as a major breakthrough in treating obesity.

The Zimulti Acomplia Report, updated daily, will track the continuing efforts of Sanofi to get rimonabant approved for sale in the U.S. The Zimulti Acomplia Report also will provide news and reviews related to rimonabant so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.

http://www.acompliareport.com/